Market Closed -
Nasdaq
21:00:00 26/06/2024 BST
|
5-day change
|
1st Jan Change
|
9.67
USD
|
+1.04%
|
|
-4.26%
|
-11.69%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
705.4
|
437.7
|
449.7
|
132
|
44.5
|
66.97
|
-
|
-
|
Enterprise Value (EV)
1 |
524.5
|
347.9
|
308.5
|
-35.31
|
-49.77
|
-21.2
|
2.732
|
-36.9
|
P/E ratio
|
-6.29
x
|
-3.99
x
|
-14.2
x
|
-0.94
x
|
-0.69
x
|
-1.94
x
|
-1.67
x
|
-1.93
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
31.7
x
|
18
x
|
3.89
x
|
5.26
x
|
0.91
x
|
2.12
x
|
3.63
x
|
3.33
x
|
EV / Revenue
|
23.6
x
|
14.3
x
|
2.67
x
|
-1.41
x
|
-1.02
x
|
-0.67
x
|
0.15
x
|
-1.84
x
|
EV / EBITDA
|
-6.41
x
|
-3.44
x
|
-10.1
x
|
0.38
x
|
1.35
x
|
0.53
x
|
-0.06
x
|
0.64
x
|
EV / FCF
|
-5.48
x
|
-3.76
x
|
-19.4
x
|
0.72
x
|
0.58
x
|
0.28
x
|
-0.05
x
|
0.79
x
|
FCF Yield
|
-18.2%
|
-26.6%
|
-5.16%
|
139%
|
173%
|
359%
|
-1,852%
|
126%
|
Price to Book
|
5.14
x
|
9.77
x
|
4.76
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,693
|
1,749
|
2,026
|
3,699
|
4,064
|
6,926
|
-
|
-
|
Reference price
2 |
416.7
|
250.2
|
222.0
|
35.70
|
10.95
|
9.670
|
9.670
|
9.670
|
Announcement Date
|
10/03/20
|
18/03/21
|
15/03/22
|
09/03/23
|
27/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
22.24
|
24.28
|
115.5
|
25.1
|
48.73
|
31.53
|
18.47
|
20.1
|
EBITDA
1 |
-81.89
|
-101.1
|
-30.42
|
-92.57
|
-36.92
|
-39.96
|
-42.31
|
-57.66
|
EBIT
1 |
-87.2
|
-109.8
|
-39.4
|
-100.4
|
-43.74
|
-56.74
|
-76.87
|
-83.46
|
Operating Margin
|
-392.14%
|
-452.25%
|
-34.11%
|
-399.9%
|
-89.76%
|
-179.93%
|
-416.18%
|
-415.32%
|
Earnings before Tax (EBT)
1 |
-92.88
|
-109
|
-30.6
|
-111.6
|
-61.32
|
-33.64
|
-64.91
|
-74.96
|
Net income
1 |
-92.88
|
-109
|
-30.6
|
-111.6
|
-61.32
|
-33.64
|
-64.91
|
-74.96
|
Net margin
|
-417.65%
|
-448.86%
|
-26.49%
|
-444.8%
|
-125.84%
|
-106.68%
|
-351.38%
|
-373.01%
|
EPS
2 |
-66.30
|
-62.70
|
-15.60
|
-38.10
|
-15.96
|
-4.976
|
-5.778
|
-5.020
|
Free Cash Flow
1 |
-95.68
|
-92.42
|
-15.91
|
-49.07
|
-86.07
|
-76.2
|
-50.6
|
-46.63
|
FCF margin
|
-430.26%
|
-380.55%
|
-13.77%
|
-195.52%
|
-176.64%
|
-241.64%
|
-273.94%
|
-232.05%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/03/20
|
18/03/21
|
15/03/22
|
09/03/23
|
27/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
6.339
|
3.317
|
3.82
|
7.363
|
10.6
|
8.78
|
19.79
|
13.12
|
7.038
|
17.58
|
8.321
|
6.654
|
5.488
|
10
|
13.7
|
EBITDA
1 |
-28.58
|
-25.38
|
-27.67
|
-20.99
|
-18.53
|
-22.51
|
-10.02
|
-10.74
|
-13.61
|
-3.044
|
-12.4
|
-12.6
|
-11.8
|
-
|
-
|
EBIT
1 |
-30.75
|
-27.35
|
-29.6
|
-22.93
|
-20.49
|
-24.46
|
-11.99
|
-12.36
|
-14.89
|
-4.187
|
-13.68
|
-15.24
|
-17.01
|
-
|
-
|
Operating Margin
|
-485.09%
|
-824.42%
|
-774.9%
|
-311.42%
|
-193.33%
|
-278.63%
|
-60.57%
|
-94.23%
|
-211.57%
|
-23.81%
|
-164.38%
|
-229.09%
|
-309.99%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-22.29
|
-28.17
|
-31.04
|
-23.95
|
-17.22
|
-25.06
|
-11.89
|
-12.11
|
-16.29
|
8.588
|
-10.72
|
-13.16
|
-15.18
|
-
|
-
|
Net income
1 |
-22.29
|
-28.17
|
-31.04
|
-23.95
|
-17.22
|
-25.06
|
-11.89
|
-8.079
|
-16.29
|
8.588
|
-10.72
|
-13.16
|
-15.18
|
-
|
-
|
Net margin
|
-351.63%
|
-849.2%
|
-812.43%
|
-325.22%
|
-162.46%
|
-285.42%
|
-60.09%
|
-61.58%
|
-231.44%
|
48.84%
|
-128.79%
|
-197.72%
|
-276.58%
|
-
|
-
|
EPS
2 |
-11.40
|
-13.80
|
-13.80
|
-6.600
|
-6.900
|
-6.900
|
-3.000
|
-2.100
|
-15.56
|
1.700
|
-1.622
|
-1.847
|
-1.908
|
-0.3900
|
-0.0700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/03/22
|
09/05/22
|
08/08/22
|
08/11/22
|
09/03/23
|
09/05/23
|
04/08/23
|
07/11/23
|
27/03/24
|
13/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
181
|
89.8
|
141
|
167
|
94.3
|
88.2
|
64.2
|
104
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-95.7
|
-92.4
|
-15.9
|
-49.1
|
-86.1
|
-76.2
|
-50.6
|
-46.6
|
ROE (net income / shareholders' equity)
|
-104%
|
-119%
|
-57.7%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-49.7%
|
-56.6%
|
-21.6%
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
186.9
|
192.7
|
141.4
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
81.10
|
25.60
|
46.60
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
24.7
|
5.03
|
5.05
|
3.32
|
1.96
|
0.3
|
1.4
|
1.77
|
Capex / Sales
|
110.92%
|
20.72%
|
4.37%
|
13.22%
|
4.02%
|
0.95%
|
7.6%
|
8.79%
|
Announcement Date
|
10/03/20
|
18/03/21
|
15/03/22
|
09/03/23
|
27/03/24
|
-
|
-
|
-
|
Last Close Price
9.67
USD Average target price
33
USD Spread / Average Target +241.26% Consensus |
1st Jan change
|
Capi.
|
---|
| -11.69% | 66.97M | | +23.13% | 46.93B | | +36.84% | 39.08B | | -8.73% | 38.48B | | +28.09% | 31.01B | | -12.26% | 26.14B | | +10.57% | 25.88B | | +32.23% | 12.53B | | -6.56% | 11.36B | | -12.56% | 10.65B |
Other Biotechnology & Medical Research
|